低VAFTP53突变AML在单中心队列中显示出明显的生物学特征
Xiaoxuan Lu1, Xiaohang Ma1, Kainan Zhang1
1Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing 100044, China.
对TP53突变性急性髓性白血病 (AML) 的10%变异性等位基因频率 (VAF) 值具有临床相关性. 低VAFTP53突变AML可能是一个独特的生物亚组,预后不佳.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 国际共识分类 (ICC) 对于TP53突变性急性髓性白血病 (AML) 使用10%的变异性等位基因频率 (VAF) 值.
- 在AML中定义致癌TP53突变的最佳VAF切线是不确定的.
- 低VAF (<10%) 的TP53-突变AML的生物学和临床特征没有得到很好的描述.
研究的目的:
- 研究TP53突变AML的临床和生物特征,以10%的VAF截止值分层.
- 为了比较TP53突变AML与VAF<10%和VAF≥10%之间的结果.
主要方法:
- 单中心回顾性队列研究.
- 基于10%的VAF截止值的TP53突变AML患者的分层.
- 组间临床,细胞遗传,分子和生存数据的比较.
主要成果:
- 在VAF<10%组显示较少的不良细胞遗传异常,但更不利的分子特征 (EVI1过度表达,更高的共突变负担,ASXL1/SRSF2突变).
- 在低VAF组中,TP53热点突变更频繁.
- 两组的预后都很差;低VAF组的生存时间从数值上来说更长,但没有统计学意义.
结论:
- 对于TP53突变的AML,ICC10%的VAF值似乎具有临床意义.
- 与VAF<10%的TP53突变AML可能代表一个独特的生物亚组.
- 需要进一步的多中心研究来验证VAF预后评估和治疗个性化值.
更多相关视频
08:53Preparation of Single-cohort Colonies and Hormone Treatment of Worker Honeybees to Analyze Physiology Associated with Role and/or Endocrine System
Published on: September 6, 2016
05:51A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
相关概念视频
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Cancers Originate from Somatic Mutations in a Single Cell
Viral Mutations
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
